Methods: We included inpatients where a T2 Candida Panel was ordered during the first 61 days of the introduction at our 373-bed community hospital. Invasive fungal disease risk factors, antifungal therapy management, T2 results, concurrent blood culture results, and time to test results were obtained through chart review.
Results: Valid T2 results were reported in 59 patients. 98% (58/59) of patients met hospital criteria for T2 in at-risk patients. Concomitant blood cultures were ordered on 38/59 (64%) patients. Antifungals had been prescribed for 11/59 patients (18.6%) prior to T2 ordering for empiric treatment of invasive fungal disease. T2 resulted in 3 to 5 hours, and was available in the hospital reporting system in an average of 6.3 hours. Of the 59 T2 results, 6/59 (10%) were positive, 5/6 (83%) C.albicans, C.tropicalis, 1/6 (17%) C.parapsilosis. Of the patients with positive T2 results none had been prescribed antifungal therapy prior to the test. Appropriate antifungal therapy with either micafungin or fluconazole was ordered in positive T2 patients within 6 hours of hospital system reporting for 5/6 (83%) and within 9 hours in 1/6 (17%). All positive T2 patients had had concomitant blood cultures drawn with 3/6 (50%) reported as positive and those cultures reported C.albicans in agreement with their T2 results. Of the 53 patients with negative T2 results, none had subsequent positive fungal blood culture results and 8 had been on antifungals. Of those 8 patients, antifungal therapy was discontinued in accordance to clinical status in all patients.
Conclusion: Early detection and identification of systemic fungal infection resulted in focused and appropriate antifungal therapy. An ASP can contribute to the optimal drug management of invasive fungal diseases by monitoring current prescribing practices supported by new rapid diagnostic technologies.